BCRX BIOCRYST PHARMACEUTICALS INC
2026Q1 · CUSIP 09058V103 · Sector: Healthcare & Biotech
Lit · Institutions accelerating in
Holders
298
Δ holders QoQ
+25
Breadth percentile
Top 12%
Whale holders
150
Δ whales
+11
Inst. holding value
$2.3B
New positions
73
Closed positions
48
Price momentum (1Q)
+29.1%
Put / Call
6/8
Breadth history (34 quarters)
Past Lit Events & Aftermath 8 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2026Q1 | Top 12% | — | — |
| 2025Q2 | Top 16% | -15.5% | -13.4% |
| 2025Q1 | Top 15% | -20.2% | -32.2% |
| 2023Q1 | Top 15% | -17.4% | -38.5% |
| 2022Q3 | Top 11% | -20.9% | -34.5% |
| 2022Q1 | Top 6% | +60.1% | +48.8% |
| 2020Q2 | Top 11% | -2.6% | +135.3% |
| 2018Q3 | Top 16% | +10.5% | -56.3% |
Options Sentiment
Put holders
6
QoQ: -3
Call holders
8
QoQ: 0
See methodology →
Fundamentals
PE (TTM)
—
EPS (TTM)
$-1.77
EPS YoY
—
Revenue (TTM)
$0.9B
Revenue YoY
+75.9%
Net margin
-51.7%
ROE
—
Debt ratio
—
FCF (TTM)
$310M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-31 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.